



Step Therapy Requirements

Effective January 1, 2024

AMANTADINE ER

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 322 MG/DAY (129 MG AND 193 MG) TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
----------	--

ANTIGOUT AGENTS

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF ALLOPURINOL TABLETS WITHIN THE PAST 120 DAYS.
----------	--

ANTI-INFLAMMATORY AGENTS - GI

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF 1 OF THE FOLLOWING:BALSALAZIDE, MESALAMINE 400 MG CAP(DRTAB), MESALAMINE DR 800 MG TAB, MESALAMINE 0.375G ER CAP,OR MESALAMINE 1.2G DR TAB WITHIN THE PAST 120 DAYS
----------	--

ANTIULCER AGENTS

Products Affected

Step 2:

- *esomeprazole magnesium dr 10 mg granules* *delayed release for susp*
- *esomeprazole magnesium dr 20 mg granules* *delayed release for susp*
- *esomeprazole magnesium dr 40 mg granules* *delayed release for susp*

Details

Criteria	PRIOR CLAIM FOR GENERIC FEDERAL LEGEND FORMULARY VERSION OF ORAL LANSOPRAZOLE CAPSULES, ESOMEPRAZOLE MAG CAPSULES, RABEPRAZOLE, OMEPRAZOLE, OR PANTOPRAZOLE WITHIN THE PAST 120 DAYS.
----------	---

ARIPIPRAZOLE ODT

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*

Details

Criteria	PRIOR CLAIM FOR ONE FORMULARY ORAL ANTIPSYCHOTIC: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE, PALIPERIDONE, LURASIDONE WITHIN THE PAST 120 DAYS.
----------	--

ASENAPINE PATCH

Products Affected

Step 2:

- SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH

Details

Criteria	CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, CLOZAPINE TAB, OLANZAPINE, IR QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE, PALIPERIDONE WITHIN PAST 365 DAYS
----------	--

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- *cyclophosphamide 25 mg capsule*
- *cyclophosphamide 25 mg tablet*
- *cyclophosphamide 50 mg capsule*
- *cyclophosphamide 50 mg tablet*
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

Criteria	IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG.
----------	--

BREXPIPRAZOLE

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	CLAIM FOR 2 FORMULARY ORAL GENERIC VERSION: LURASIDONE, RISPERIDONE, OLANZAPINE, QUETIAPINE, ARIPRAZOLE, ZIPRASIDONE IN PAST 365 DAYS
----------	---

CARIPRAZINE

Products Affected

Step 2:

- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE WITHIN THE PAST 365 DAYS
----------	--

CENOBAMATE

Products Affected

Step 2:

- XCOPRI 100 MG TABLET
- XCOPRI 150 MG TABLET
- XCOPRI 200 MG TABLET
- XCOPRI 50 MG TABLET
- XCOPRI MAINTENANCE PACK 250MG/DAY (150 MG X 1 AND 100 MG X 1) TABLETS
- XCOPRI MAINTENANCE PACK 350 MG/DAY (200 MG X 1 AND 150 MG X 1) TABLETS
- XCOPRI TITRATION PACK 12.5 MG (14)-25 MG (14) TABLETS IN A DOSE PACK
- XCOPRI TITRATION PACK 150 MG (14)-200 MG (14) TABLETS IN A DOSE PACK
- XCOPRI TITRATION PACK 50 MG (14)-100 MG (14) TABLETS IN A DOSE PACK

Details

Criteria	PRIOR CLAIM FOR GENERIC ANTICONVULSANT AGENT (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, ZONISAMIDE OR LACOSAMIDE), WITHIN THE PAST 120 DAYS.
----------	---

CLOZAPINE

Products Affected

Step 2:

- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- VERSACLOZ 50 MG/ML ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR LURASIDONE AND ONE FORMULARY ORAL ANTIPSYCHOTIC: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE, PALIPERIDONE WITHIN THE PAST 365 DAYS.
----------	---

DEXTROMETHORPHAN HBR/BUPROPION

Products Affected

Step 2:

- AUVELITY 45 MG-105 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR TRINTELLIX AND ONE GENERIC ANTIDEPRESSANT (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, DESVENLAFAXINE, DULOXETINE, VENLAFAXINE, MIRTAZAPINE, BUPROPION IR/SR/XL, OR VILAZODONE) WITHIN THE PAST 365 DAYS
----------	--

DIHYDROERGOTAMINE MESYLATE

Products Affected

Step 2:

- *dihydroergotamine 0.5 mg/pump act. (4 mg/ml) nasal spray*

Details

Criteria	PRIOR CLAIM FOR 2 FORMULARY GENERIC TRIPTANS (e.g. SUMATRIPTAN and RIZATRIPTAN) WITHIN THE PAST 365 DAYS
----------	--

DULAGLUTIDE

Products Affected

Step 2:

- TRULICITY 0.75 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- TRULICITY 1.5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- TRULICITY 3 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- TRULICITY 4.5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR

Details

Criteria	ST Criteria: Pending CMS Approval
----------	-----------------------------------

DULOXETINE SPRINKLE

Products Affected

Step 2:

- DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE

Details

Criteria	PRIOR CLAIM FOR FORMULARY GENERIC DULOXETINE CAPSULE WITHIN THE PAST 120 DAYS.
----------	--

EPRONTIA

Products Affected

Step 2:

- EPRONTIA 25 MG/ML ORAL SOLUTION

Details

Criteria	PRIOR CLAIM FOR GENERIC TOPIRAMATE IMMEDIATE RELEASE (IR) OR EXTENDED RELEASE (ER) WITHIN THE PAST 120 DAYS.
----------	--

ESLICARBAZEPINE ACETATE

Products Affected

Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET

Details

Criteria	PRIOR CLAIM FOR 2 GENERIC ANTICONVULSANT AGENTS (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, ZONISAMIDE OR LACOSAMIDE), WITHIN THE PAST 365 DAYS.
----------	--

FIBRATES

Products Affected

Step 2:

- *omega-3 acid ethyl esters 1 gram capsule*

Details

Criteria	PRIOR CLAIM FOR GENERIC FENOFIBRATE IN THE LAST 120 DAY
----------	---

ILOPERIDONE

Products Affected

Step 2:

- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET

Details

Criteria	CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, CLOZAPINE TAB, OLANZAPINE, IR QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE, PALIPERIDONE WITHIN THE PAST 365 DAYS.
----------	---

KETOCONAZOLE TOPICAL

Products Affected

Step 2:

- *ketoconazole 2 % topical foam*

Details

Criteria	PRIOR CLAIM OF FORMULARY VERSION KETOCONAZOLE CREAM IN THE PAST 120 DAYS
----------	---

LEVOMILNACIPRAN

Products Affected

Step 2:

- FETZIMA 120 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR TRINTELLIX AND 1 GENERIC ANTIDEPRESSANT: BUPROPION, CITALOPRAM, ESCITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE, or VILAZODONE IN THE PAST 365 DAYS
----------	--

LUMATEPERONE TOSYLATE

Products Affected

Step 2:

- CAPLYTA 10.5 MG CAPSULE
- CAPLYTA 21 MG CAPSULE
- CAPLYTA 42 MG CAPSULE

Details

Criteria	CLAIM FOR 2 FORMULARY ORAL GENERIC ANTIPSYCHOTICS: LURASIDONE, RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, ASENAPINE WITHIN THE PAST 365 DAYS
----------	--

MEMANTINE ER

Products Affected

Step 2:

- *memantine 14 mg capsule sprinkle, extended release 24hr*
- *memantine 21 mg capsule sprinkle, extended release 24hr*
- *memantine 28 mg capsule sprinkle, extended release 24hr*
- *memantine 7 mg capsule sprinkle, extended release 24hr*

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF MEMANTINE IR WITHIN THE PAST 120 DAYS
----------	--

NASAL CORTICOSTEROIDS II

Products Affected

Step 2:

- XHANCE 93 MCG/ACTUATION
BREATH ACTIVATED AEROSOL

Details

Criteria	PRIOR CLAIM FOR A FEDERAL LEGEND FORMULARY VERSION OF MOMETASONE NASAL SPRAY WITHIN THE PAST 120 DAYS
----------	---

NOVEL ORAL ANTICOAGULANTS

Products Affected

Step 2:

- *dabigatran etexilate 150 mg capsule*
- *dabigatran etexilate 75 mg capsule*

Details

Criteria	PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS.
----------	---

OPHTHALMIC ALLERGY - NO OTC

Products Affected

Step 2:

- ALREX 0.2 % EYE
DROPS,SUSPENSION

Details

Criteria	PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE , CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS.
----------	---

PERAMPANEL

Products Affected

Step 2:

- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET

Details

Criteria	PRIOR CLAIM FOR 2 GENERIC ANTICONVULSANT AGENTS (CARBAMAZEPINE, DIVALPROEX SODIUM, GABAPENTIN, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, TIAGABINE, TOPIRAMATE, VALPROIC ACID, ZONISAMIDE OR LACOSAMIDE), WITHIN THE PAST 365 DAYS.
----------	--

RUFINAMIDE

Products Affected

Step 2:

- *rufinamide 200 mg tablet*
- *rufinamide 40 mg/ml oral suspension*
- *rufinamide 400 mg tablet*

Details

Criteria	ST Criteria: Pending CMS Approval
----------	-----------------------------------

SELEGILINE PATCH

Products Affected

Step 2:

- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH

Details

Criteria	PRIOR CLAIM OF FORMULARY ORAL VERSION OF SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE), SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE), MIRTAZAPINE, OR BUPROPION IR/SR/XL IN THE PAST 120 DAYS
----------	---

SEMAGLUTIDE

Products Affected

Step 2:

- OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- OZEMPIC 0.25 MG OR 0.5 MG (2 MG/3 ML) SUBCUTANEOUS PEN INJECTOR
- OZEMPIC 1 MG/DOSE (4 MG/3 ML) SUBCUTANEOUS PEN INJECTOR
- OZEMPIC 2 MG/DOSE (8 MG/3 ML) SUBCUTANEOUS PEN INJECTOR
- RYBELSUS 14 MG TABLET
- RYBELSUS 3 MG TABLET
- RYBELSUS 7 MG TABLET

Details

Criteria	ST Criteria: Pending CMS Approval
----------	-----------------------------------

SPRITAM

Products Affected

Step 2:

- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS
----------	---

TACROLIMUS PACKETS

Products Affected

Step 2:

- PROGRAF 0.2 MG ORAL GRANULES IN PACKET
- PROGRAF 1 MG ORAL GRANULES IN PACKET

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF TACROLIMUS IR CAPSULES WITHIN THE PAST 120 DAYS
----------	--

TENOFOVIR ALAFENAMIDE

Products Affected

Step 2:

- VEMLIDY 25 MG TABLET

Details

Criteria	TRIAL OF GENERIC TENOFOVIR DISOPROXIL FUMARATE WITHIN THE PAST 120 DAYS
----------	--

TIRZEPATIDE-MOUNJARO

Products Affected

Step 2:

- MOUNJARO 10 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- MOUNJARO 12.5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- MOUNJARO 15 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- MOUNJARO 2.5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- MOUNJARO 5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR
- MOUNJARO 7.5 MG/0.5 ML
SUBCUTANEOUS PEN INJECTOR

Details

Criteria	TRIAL OF METFORMIN, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE, PIOGLITAZONE OR A COMBINATION PRODUCT CONTAINING ANY OF THE AFOREMENTIONED AGENTS WITHIN THE PAST 120 DAYS
----------	---

INDEX

ALREX 0.2 % EYE		<i>esomeprazole magnesium dr 10 mg</i>	
DROPS,SUSPENSION	26	<i>granules delayed release for susp</i>	4
APTiom 200 MG TABLET	17	<i>esomeprazole magnesium dr 20 mg</i>	
APTiom 400 MG TABLET	17	<i>granules delayed release for susp</i>	4
APTiom 600 MG TABLET	17	<i>esomeprazole magnesium dr 40 mg</i>	
APTiom 800 MG TABLET	17	<i>granules delayed release for susp</i>	4
<i>aripiprazole 10 mg disintegrating tablet</i>	5	FANAPT 1 MG TABLET	19
<i>aripiprazole 15 mg disintegrating tablet</i>	5	FANAPT 10 MG TABLET	19
AUVELITY 45 MG-105 MG TABLET,		FANAPT 12 MG TABLET	19
EXTENDED RELEASE	12	FANAPT 1MG(2)-2 MG(2)-4MG(2)-6	
CAPLYTA 10.5 MG CAPSULE	22	MG(2) TABLETS IN A DOSE PACK ...	19
CAPLYTA 21 MG CAPSULE	22	FANAPT 2 MG TABLET	19
CAPLYTA 42 MG CAPSULE	22	FANAPT 4 MG TABLET	19
<i>clozapine 100 mg disintegrating tablet</i>	11	FANAPT 6 MG TABLET	19
<i>clozapine 12.5 mg disintegrating tablet</i>	11	FANAPT 8 MG TABLET	19
<i>clozapine 150 mg disintegrating tablet</i>	11	<i>febuxostat 40 mg tablet</i>	2
<i>clozapine 200 mg disintegrating tablet</i>	11	<i>febuxostat 80 mg tablet</i>	2
<i>clozapine 25 mg disintegrating tablet</i>	11	FETZIMA 120 MG	
<i>cyclophosphamide 25 mg capsule</i>	7	CAPSULE,EXTENDED RELEASE	21
<i>cyclophosphamide 25 mg tablet</i>	7	FETZIMA 20 MG (2)-40 MG (26)	
<i>cyclophosphamide 50 mg capsule</i>	7	CAPSULE,EXTENDED RELEASE,24	
<i>cyclophosphamide 50 mg tablet</i>	7	HR,DOSE PACK	21
<i>dabigatran etexilate 150 mg capsule</i>	25	FETZIMA 20 MG	
<i>dabigatran etexilate 75 mg capsule</i>	25	CAPSULE,EXTENDED RELEASE	21
<i>dihydroergotamine 0.5 mg/pump act. (4</i>		FETZIMA 40 MG	
<i>mg/ml) nasal spray</i>	13	CAPSULE,EXTENDED RELEASE	21
DIPENTUM 250 MG CAPSULE	3	FETZIMA 80 MG	
DRIZALMA SPRINKLE 20 MG		CAPSULE,EXTENDED RELEASE	21
CAPSULE,DELAYED RELEASE	15	FYCOMPA 0.5 MG/ML ORAL	
DRIZALMA SPRINKLE 30 MG		SUSPENSION	27
CAPSULE,DELAYED RELEASE	15	FYCOMPA 10 MG TABLET	27
DRIZALMA SPRINKLE 40 MG		FYCOMPA 12 MG TABLET	27
CAPSULE,DELAYED RELEASE	15	FYCOMPA 2 MG TABLET	27
DRIZALMA SPRINKLE 60 MG		FYCOMPA 4 MG TABLET	27
CAPSULE,DELAYED RELEASE	15	FYCOMPA 6 MG TABLET	27
EMSAM 12 MG/24 HR		FYCOMPA 8 MG TABLET	27
TRANSDERMAL 24 HOUR PATCH ...	29	<i>ketoconazole 2 % topical foam</i>	20
EMSAM 6 MG/24 HR		<i>memantine 14 mg capsule</i>	
TRANSDERMAL 24 HOUR PATCH ...	29	<i>sprinkle,extended release 24hr</i>	23
EMSAM 9 MG/24 HR		<i>memantine 21 mg capsule</i>	
TRANSDERMAL 24 HOUR PATCH ...	29	<i>sprinkle,extended release 24hr</i>	23
EPRONTIA 25 MG/ML ORAL		<i>memantine 28 mg capsule</i>	
SOLUTION	16	<i>sprinkle,extended release 24hr</i>	23

<i>memantine 7 mg capsule</i>		<i>rufinamide 200 mg tablet</i>	28
<i>sprinkle, extended release 24hr</i>	23	<i>rufinamide 40 mg/ml oral suspension</i>	28
<i>methotrexate sodium 2.5 mg tablet</i>	7	<i>rufinamide 400 mg tablet</i>	28
MOUNJARO 10 MG/0.5 ML		RYBELSUS 14 MG TABLET	30
SUBCUTANEOUS PEN INJECTOR	34	RYBELSUS 3 MG TABLET	30
MOUNJARO 12.5 MG/0.5 ML		RYBELSUS 7 MG TABLET	30
SUBCUTANEOUS PEN INJECTOR	34	SECUADO 3.8 MG/24 HOUR	
MOUNJARO 15 MG/0.5 ML		TRANSDERMAL 24 HOUR PATCH	6
SUBCUTANEOUS PEN INJECTOR	34	SECUADO 5.7 MG/24 HOUR	
MOUNJARO 2.5 MG/0.5 ML		TRANSDERMAL 24 HOUR PATCH	6
SUBCUTANEOUS PEN INJECTOR	34	SECUADO 7.6 MG/24 HOUR	
MOUNJARO 5 MG/0.5 ML		TRANSDERMAL 24 HOUR PATCH	6
SUBCUTANEOUS PEN INJECTOR	34	SPRITAM 1,000 MG TABLET FOR	
MOUNJARO 7.5 MG/0.5 ML		ORAL SUSPENSION	31
SUBCUTANEOUS PEN INJECTOR	34	SPRITAM 250 MG TABLET FOR	
<i>omega-3 acid ethyl esters 1 gram capsule</i> ..	18	ORAL SUSPENSION	31
OSMOLEX ER 129 MG TABLET,		SPRITAM 500 MG TABLET FOR	
EXTENDED RELEASE	1	ORAL SUSPENSION	31
OSMOLEX ER 193 MG TABLET,		SPRITAM 750 MG TABLET FOR	
EXTENDED RELEASE	1	ORAL SUSPENSION	31
OSMOLEX ER 258 MG TABLET,		TRULICITY 0.75 MG/0.5 ML	
EXTENDED RELEASE	1	SUBCUTANEOUS PEN INJECTOR	14
OSMOLEX ER 322 MG/DAY (129 MG		TRULICITY 1.5 MG/0.5 ML	
AND 193 MG) TABLET, EXTENDED		SUBCUTANEOUS PEN INJECTOR	14
RELEASE	1	TRULICITY 3 MG/0.5 ML	
OZEMPIC 0.25 MG OR 0.5 MG (2		SUBCUTANEOUS PEN INJECTOR	14
MG/1.5 ML) SUBCUTANEOUS PEN		TRULICITY 4.5 MG/0.5 ML	
INJECTOR	30	SUBCUTANEOUS PEN INJECTOR	14
OZEMPIC 0.25 MG OR 0.5 MG (2		VEMLIDY 25 MG TABLET	33
MG/3 ML) SUBCUTANEOUS PEN		VERSACLOZ 50 MG/ML ORAL	
INJECTOR	30	SUSPENSION	11
OZEMPIC 1 MG/DOSE (4 MG/3 ML)		VRAYLAR 1.5 MG (1)-3 MG (6)	
SUBCUTANEOUS PEN INJECTOR	30	CAPSULES IN A DOSE PACK	9
OZEMPIC 2 MG/DOSE (8 MG/3 ML)		VRAYLAR 1.5 MG CAPSULE	9
SUBCUTANEOUS PEN INJECTOR	30	VRAYLAR 3 MG CAPSULE	9
PROGRAF 0.2 MG ORAL		VRAYLAR 4.5 MG CAPSULE	9
GRANULES IN PACKET	32	VRAYLAR 6 MG CAPSULE	9
PROGRAF 1 MG ORAL GRANULES		XATMEP 2.5 MG/ML ORAL	
IN PACKET	32	SOLUTION	7
REXULTI 0.25 MG TABLET	8	XCOPRI 100 MG TABLET	10
REXULTI 0.5 MG TABLET	8	XCOPRI 150 MG TABLET	10
REXULTI 1 MG TABLET	8	XCOPRI 200 MG TABLET	10
REXULTI 2 MG TABLET	8	XCOPRI 50 MG TABLET	10
REXULTI 3 MG TABLET	8		
REXULTI 4 MG TABLET	8		

XCOPRI MAINTENANCE PACK 250MG/DAY (150 MG X 1 AND 100 MG X 1) TABLETS.....	10
XCOPRI MAINTENANCE PACK 350 MG/DAY (200 MG X 1 AND 150 MG X 1) TABLETS.....	10
XCOPRI TITRATION PACK 12.5 MG (14)-25 MG (14) TABLETS IN A DOSE PACK.....	10
XCOPRI TITRATION PACK 150 MG (14)-200 MG (14) TABLETS IN A DOSE PACK.....	10
XCOPRI TITRATION PACK 50 MG (14)-100 MG (14) TABLETS IN A DOSE PACK.....	10
XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL.....	24